Decitabine
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid M.D. Anderson Cancer Center | Phase 2 | CCC |
Idarubicine M.D. Anderson Cancer Center | Phase 2 | CCC |
Gemtuzumab Ozogamicin M.D. Anderson Cancer Center | Phase 2 | CCC |
Fludarabine M.D. Anderson Cancer Center | Phase 2 | CCC |
FILGRASTIM-SNDZ M.D. Anderson Cancer Center | Phase 2 | CC |
Same molecule, other indications
Decitabine is also rated in:
acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant
BB
Indicative ·
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →